Sugi Predict

Sugi Predict / Compounds / SCHEMBL5223432

SCHEMBL5223432

SCHEMBL5223432

Cc1cn([C@@]2([SiH](c3ccccc3)c3ccccc3)C[C@H](OC(C)(C)C)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ RNASE1 P07998 1/20 0.41
▸ TK1 P04183 6/20 0.35
▸ TK2 O00142 3/20 0.35
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7510541 0.90 HPGD (0.33) RNASE1TK1TK2HPGD
SCHEMBL7539785 0.87 RNASE1 (0.39) RNASE1TK1TK2
SCHEMBL2056759 0.87 TK1 (0.39) RNASE1TK1
SCHEMBL7517373 0.87 RNASE1 (0.33) RNASE1TK1HPGD
SCHEMBL6244002 0.82 TK1 (0.36) RNASE1TK1TK2HPGD
SCHEMBL8176133 0.80 TK2 (0.33) RNASE1TK1TK2HPGD
SCHEMBL8424864 0.80 ALDH1A1 (0.35) RNASE1TK1
SCHEMBL7922853 0.80 TK2 (0.34) RNASE1TK1TK2HPGD
SCHEMBL7917893 0.79 RNASE1 (0.33) RNASE1TK1TK2
SCHEMBL8906740 0.78 TK1 (0.36) TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3647318-B1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS INC (US) 2021-06-30 — — EP disclosed
EP-3647318-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS Ionis Pharmaceuticals, Inc. (US) 2020-05-06 — — EP disclosed
EP-3137476-B1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS INC (US) 2019-10-09 — — EP disclosed
US-10344275-B2 Linkage modified oligomeric compounds IONIS PHARMACEUTICALS, INC. (US) 2019-07-09 — — US disclosed
US-20180305687-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2018-10-25 — — US disclosed
US-9926556-B2 Linkage modified oligomeric compounds IONIS PHARMACEUTICALS, INC. (US) 2018-03-27 — — US disclosed
US-20170044526-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2017-02-16 — — US disclosed
US-20070292875-A1 Human RNase H1 oligonucleotide compositions thereof ISIS PHARMACEUTICALS, INC. (US) 2007-12-20 — — US disclosed
US-20070123702-A1 Oligonucleotdies having A-DNA form and B-DNA form conformational geometry MANOHARAN MUTHIAH 2007-05-31 — — US disclosed
EP-1743901-A2 Oligonucleotides having A-DNA or B-DNA form ISIS PHARMACEUTICALS, INC. (US) 2007-01-17 — — EP disclosed
US-7119184-B2 Oligonucleotides having A-DNA form and B-DNA form conformational geometry ISIS PHARMACEUTICALS, INC. (US) 2006-10-10 — — US disclosed
EP-1222309-B1 HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF ISIS PHARMACEUTICALS INC (US) 2005-12-07 — — EP disclosed
US-6811975-B2 MIMIC OR MODULATE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS THEREBY AFFECTING PROTEIN PRODUCTION OR ACTIVITY ISIS PHARMACEUTICALS, INC. 2004-11-02 — — US disclosed
US-20040102618-A1 Human RNase H1 and oligonucleotide compositions thereof ISIS PHARMACEUTICALS, INC. 2004-05-27 — — US disclosed
US-6737520-B2 FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE ISIS PHARMACEUTICALS, INC. 2004-05-18 — — US disclosed
US-20030105311-A1 Oligonucleotides having A-DNA form and B-DNA form conformational geometry ISIS PHARMACEUTICALS, INC. 2003-06-05 — — US disclosed
US-20030096979-A1 Oligonucleotides having A-DNA form and B-DNA form conformational geometry ISIS PHARMACEUTICALS, INC. 2003-05-22 — — US disclosed
US-6369209-B1 AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND ISIS PHARMACEUTICALS, INC. 2002-04-09 — — US disclosed
US-20010027251-A1 Phosphorothioate oligonucleotides having modified internucleoside linkages ISIS PHARMACEUTICALS, INC. 2001-10-04 — — US disclosed
US-6242589-B1 RESISTANT TO NUCLEASE DEGRADATION AND GOOD HYBRIDIZATION CHARACTERISTICS; ANTISENSE AGENTS FOR DIAGNOSIS AND THERAPY ISIS PHARMACEUTICALS, INC. 2001-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105311-A1 Oligonucleotides having A-DNA form and B-DNA form conformational geometry RNGTT, RNASEH1, ADAR RNASE1 5/4885TK1 661/4885TK2 1005/4885
US-20070292875-A1 Human RNase H1 oligonucleotide compositions thereof RNASEH1, RNASE1, RNASEL RNASE1 2/4885TK1 407/4885TK2 272/4885
US-20030096979-A1 Oligonucleotides having A-DNA form and B-DNA form conformational geometry RNGTT, RNASEH1, ADAR RNASE1 5/4885TK1 661/4885TK2 1005/4885
US-20040102618-A1 Human RNase H1 and oligonucleotide compositions thereof RNASEH1, RNASE1, RNASEL RNASE1 2/4885TK1 433/4885TK2 260/4885
US-20180305687-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS PHAX, HNRNPM, HNRNPAB RNASE1 50/4885TK1 209/4885TK2 376/4885
US-20070123702-A1 Oligonucleotdies having A-DNA form and B-DNA form conformational geometry RNASEH1, RNGTT, ADAR RNASE1 5/4885TK1 550/4885TK2 853/4885
US-20010027251-A1 Phosphorothioate oligonucleotides having modified internucleoside linkages TYMP, DTYMK, RNGTT RNASE1 65/4885TK1 44/4885TK2 78/4885
US-10344275-B2 Linkage modified oligomeric compounds PHAX, HNRNPM, HNRNPAB RNASE1 50/4885TK1 209/4885TK2 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.